Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
LGDN:FRA
Ligand Pharmaceuticals Inc
193,00 €
+2,66%
(+5,00) 1D
4 մյս, 08:58:24 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LGDN...
Open
193,00 €
High
193,00 €
Low
193,00 €
Mkt. cap
4,56 մլրդ
Avg. vol.
3,00
Volume
0,00
52-wk high
204,00 €
52-wk low
87,00 €
No. of employees
47
News stories
From sources across the web
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
Foundedսեպ 1987
HeadquartersJupiter, Ֆլորիդա, Միացյալ Նահանգներ
Sector-
Websiteligand.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
45,33 մլն
47,63 մլն
115,46 մլն
59,67 մլն
Cost of goods sold
54,93 մլն
9,47 մլն
24,82 մլն
6,50 մլն
Cost of revenue
54,93 մլն
9,47 մլն
24,82 մլն
6,50 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,80 մլն
20,18 մլն
28,45 մլն
25,03 մլն
Operating expense
27,06 մլն
28,43 մլն
36,54 մլն
33,12 մլն
Total operating expenses
81,99 մլն
37,91 մլն
61,36 մլն
39,63 մլն
Operating income
-36,66 մլն
9,72 մլն
54,10 մլն
20,04 մլն
Other non operating income
-2,06 մլն
96,00 հզր
390,00 հզր
1,48 մլն
EBT including unusual items
-50,18 մլն
11,22 մլն
141,14 մլն
56,78 մլն
EBT excluding unusual items
-37,81 մլն
10,28 մլն
57,45 մլն
116,80 մլն
Income tax expense
-7,73 մլն
6,38 մլն
23,86 մլն
12,00 մլն
Effective tax rate
15,40%
56,81%
16,91%
21,13%
Other operating expenses
-
-
-
-
Net income
-42,45 մլն
4,85 մլն
117,27 մլն
44,78 մլն
Net profit margin
-93,64%
10,18%
101,57%
75,06%
Earnings per share
1,33
1,60
3,09
2,02
Interest and investment income
1,77 մլն
1,62 մլն
3,87 մլն
6,39 մլն
Interest expense
-867,00 հզր
-1,15 մլն
-910,00 հզր
-1,78 մլն
Net interest expenses
904,00 հզր
468,00 հզր
2,96 մլն
4,61 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-28,35 մլն
17,82 մլն
63,26 մլն
28,25 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer